Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Kavanagh, Joanne E., Hearn, Andrew P., Dhariwal, Jaideep, d’Ancona, Gráinne, Douiri, Abdel, Roxas, Cris, Fernandes, Mariana, Green, Linda, Thomson, Louise, Nanzer, Alexandra M., Kent, Brian D., Jackson, David J.·2021·Chest

Abstract

BACKGROUND Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in reducing asthma exacerbation rates and maintenance oral corticosteroids (mOCS). RESEARCH QUESTION Our aim was to evaluate the real-world effectiveness of benralizumab and identify any baseline characteristics associated with response to therapy. STUDY DESIGN & Methods: We assessed outcomes in all SEA patients commenced on benralizumab at our specialist centre. At each dosing visit, exacerbation history, mOCS dose, spirometry, Asthma Control Questionnaire (ACQ6) and mini-Asthma Quality of Life Questionnaire (mAQLQ) scores were recorded. Response to treatment was defined as a reduction of ≥50% in annualised exacerbation rate (AER) or in mOCS dose after 48 weeks of treatment. Super-response was defined as zero exacerbations and no mOCS for asthma. RESULTS 130 patients were included in the analysis. At 48 weeks there was a 72.8% reduction in AER, from 4.92±3.35 in the year preceding biologic treatment to 1.34±1.71 (p<0.001), including 57(43.8%) patients who were exacerbation-free on benralizumab. In those on mOCS (n=74; 56.9%), the median daily prednisolone dose fell from 10mg (5-20) to 0mg (0-5) (p<0.001), and 38/74(51.4%) were able to discontinue mOCS. There were clinically and statistically significant improvements in ACQ6, mAQLQ and FEV1. Overall, 51 (39%) met the super-responder definition, and 112(86%) the responder definition. The optimal regression model of super-responders versus other responders included baseline characteristics associated with a strongly eosinophilic phenotype and less severe disease. Eighteen (13.8%) patients were non-responders to benralizumab. Evidence of chronic airway infection was observed in 6/18 and an increase in the blood eosinophil count consistent with the development of anti-drug antibodies in 5/18. INTERPRETATION In a large real-world SEA cohort, benralizumab led to significant improvements in all clinical outcome measures. A lack of response was seen in a minority and should be a focus for future investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2020.08.2083

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 263

Metadata

Authors
Kavanagh, J. E., Hearn, A. P., Dhariwal, J., d’Ancona, G., Douiri, A., Roxas, C., Fernandes, M., Green, L., Thomson, L., Nanzer, A. M., Kent, B. D., & Jackson, D. J.
Venue
Chest
Publisher
Elsevier BV
Published
2021-02
Volume
159
Issue
2
Pages
496-506
ISSN
0012-3692 (ISSN-L)
OpenAlex
W3082062213
Cited by
263
References
19
FWCI
21.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. https://app.cochat.ai/papers/10.1016/j.chest.2020.08.2083
The paper
Kavanagh, J. E., Hearn, A. P., Dhariwal, J., d’Ancona, G., Douiri, A., Roxas, C., Fernandes, M., Green, L., Thomson, L., Nanzer, A. M., Kent, B. D., & Jackson, D. J. (2021). Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. https://doi.org/10.1016/j.chest.2020.08.2083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.